-Reuters
Compass Pathways’ Psilocybin Therapy Shows Mixed Results From Depression Trial
​​​​​Compass Pathways plc (NASDAQ:CMPS) has announced results from Phase 2b trial of COMP360 psilocybin therapy for treatment-resistant depression. The study has…